By proceeding, you agree to our Terms of Use and Privacy Policy.
Bart Anderson is the Senior Director, R&D at Exicure, where he leads preclinical discovery and development efforts across all mechanisms of action and therapeutic areas.
Talks About #molecularbiology #genetics #neuroscience
Preferred Locations #NorthAmerica
Oligonucleotide Therapeutics - the emerging medicine class - are harnessing the therapeutic benefit of targeting genetic material utilising oligonucleotide conjugates, antisense oligonucleotides (ASOs), mRNA and RNAi.
